MX2021001063A - Dispersion solida de derivado de hidantoina. - Google Patents

Dispersion solida de derivado de hidantoina.

Info

Publication number
MX2021001063A
MX2021001063A MX2021001063A MX2021001063A MX2021001063A MX 2021001063 A MX2021001063 A MX 2021001063A MX 2021001063 A MX2021001063 A MX 2021001063A MX 2021001063 A MX2021001063 A MX 2021001063A MX 2021001063 A MX2021001063 A MX 2021001063A
Authority
MX
Mexico
Prior art keywords
solid dispersion
hydantoin derivative
pharmaceutically acceptable
hydantoin
derivative
Prior art date
Application number
MX2021001063A
Other languages
English (en)
Inventor
Takamitsu Ueto
Ryo Kinoshita
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2021001063A publication Critical patent/MX2021001063A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Una dispersión sólida de acuerdo con la presente invención comprende: un compuesto I que tiene la fórmula estructural; (ver Fórmula) un polímero farmacéuticamente aceptable; y especies catiónicas farmacéuticamente aceptables.
MX2021001063A 2018-07-30 2019-07-29 Dispersion solida de derivado de hidantoina. MX2021001063A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018142048 2018-07-30
PCT/JP2019/029564 WO2020027011A1 (ja) 2018-07-30 2019-07-29 ヒダントイン誘導体の固体分散体

Publications (1)

Publication Number Publication Date
MX2021001063A true MX2021001063A (es) 2021-04-12

Family

ID=69232476

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001063A MX2021001063A (es) 2018-07-30 2019-07-29 Dispersion solida de derivado de hidantoina.

Country Status (12)

Country Link
US (1) US20210290541A1 (es)
EP (1) EP3831381A4 (es)
JP (1) JPWO2020027011A1 (es)
KR (1) KR20210038614A (es)
CN (1) CN112770750A (es)
AU (1) AU2019313853A1 (es)
BR (1) BR112021001170A2 (es)
CA (1) CA3107665A1 (es)
IL (1) IL280411A (es)
MX (1) MX2021001063A (es)
TW (1) TW202019416A (es)
WO (1) WO2020027011A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW486370B (en) * 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
DE60237602D1 (de) 2001-06-22 2010-10-21 Bend Res Inc Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere
KR100758045B1 (ko) 2002-02-01 2007-09-11 화이자 프로덕츠 인크. 압력 노즐을 이용하여 균질한 분무 건조된 비결정질 고체약물 분산제를 제조하는 방법
ATE476966T1 (de) * 2006-10-17 2010-08-15 Bend Res Inc Feste dispersion mit schwer wasserlöslichem wirkstoff
WO2010126030A1 (ja) 2009-04-28 2010-11-04 中外製薬株式会社 スピロイミダゾロン誘導体
MX2013010306A (es) * 2011-03-08 2013-12-09 Zalicus Pharmaceuticals Ltd Formulaciones de dispersion solida y metodos de uso de las mismas.
EP2572731A1 (en) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions
JP5951799B2 (ja) 2012-12-10 2016-07-13 中外製薬株式会社 ヒダントイン誘導体
EP2956121B1 (en) * 2013-02-12 2018-05-30 Bend Research, Inc. Solid dispersions of low-water solubility actives
CN106572994B (zh) * 2014-06-09 2020-09-18 中外制药株式会社 含有乙内酰脲衍生物的药物组合物
CN110121348A (zh) * 2016-12-28 2019-08-13 中外制药株式会社 包含ed－71的固体分散体及油分散体的药物组合物
KR101912224B1 (ko) * 2017-02-20 2018-10-26 충남대학교산학협력단 타다라필 함유 고체 분산체, 이를 포함하는 약제학적 조성물 및 이의 제조방법

Also Published As

Publication number Publication date
US20210290541A1 (en) 2021-09-23
JPWO2020027011A1 (ja) 2021-08-02
EP3831381A4 (en) 2022-05-04
BR112021001170A2 (pt) 2021-04-27
EP3831381A1 (en) 2021-06-09
KR20210038614A (ko) 2021-04-07
TW202019416A (zh) 2020-06-01
WO2020027011A1 (ja) 2020-02-06
CN112770750A (zh) 2021-05-07
CA3107665A1 (en) 2020-02-06
IL280411A (en) 2021-03-25
AU2019313853A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
EP4321513A3 (en) Pyrrolotriazine compounds as tam inhibitors
TN2019000192A1 (en) Pyrazole derivatives as malt1 inhibitors
MX2019001096A (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
WO2017176957A8 (en) Mdm2 protein degraders
AU2017343793B2 (en) Pyrrolobenzodiazepine conjugates
WO2019132561A8 (ko) 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
MA42339A1 (fr) Modulateurs du récepteur farnésoïde x
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
TN2017000204A1 (en) Triazolopyrimidine compounds and uses thereof
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
AU2020317609A8 (en) Novel heteroaryl-triazole compounds as pesticides
EP4316591A3 (en) Oxysterols and methods of use thereof
EP4001273A3 (en) Aminopyrimidines as alk inhibitors
PH12020551013A1 (en) Oxy-fluoropiperidine derivative as kinase inhibitor
MX2015011913A (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
AU2018274723A1 (en) Benzimidazolone derived inhibitors of BCL6
EA201792478A1 (ru) Соединения-ингибиторы передачи сигналов пути notch
MX366820B (es) Moduladores de gpr120 del acido biciclo[2.2.2].
MX2020014097A (es) Lipidos novedosos.
NZ746906A (en) Oxaborole esters and uses thereof
JOP20200030A1 (ar) مركب خماسي الحلقة
AU2018316542A1 (en) Indole derivatives as histone demethylase inhibitors
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
MX2021004386A (es) Compuestos novedosos.
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor